MET
Metabolic
GLP-1 and amylin analogs. The only group in this category with large completed human trials behind it, and the only one where the regulator has already acted.
8 compounds
NOTHING FOR SALE · READ AT THE SOURCE
Every claim about every peptide, graded.
The grades run from human trials down to anecdote, and every one carries the citations behind it. We don't sell anything, so we don't need any claim to be true.
Click any node to name the compound it carries.
field compounds · links · 0 opened
“We report what has been documented. We do not prescribe what should be done.”
The editorial policy, in one line
coverage
Four groups, covered in the depth each one earns
Every compound answers the same four questions: what it is, what was studied, what the studies actually showed, and where the regulator stands today. A compound gets its own page where there is enough sourced material to earn one, and a substantial entry inside its category page where there is not. A letter grade appears only where this site has run its own source review, which is 15 of 54 compounds so far; the rest are on the compound index. Nothing here tells anyone to take anything, and no page on this site publishes an amount for a person.
REP
Repair and recovery
Tissue-repair compounds. The best-selling group in the market and among the thinnest on human evidence, which is the single most useful fact a reader can leave with.
7 compounds
GHS
Secretagogues
Growth-hormone-releasing peptides and ghrelin-receptor agonists. Mostly studied as short endocrine experiments rather than as anything a person would use.
9 compounds
LNG
Longevity and cognitive
Bioregulators and neuropeptides. The group with the widest gap between what the marketing says and what the published research covers, which is where the grading earns its keep.
13 compounds
compounds
The index
6 shown, out of the whole category on the compound index. Each card carries the group, the evidence grade, the number of completed human studies of that compound, and the regulatory position. The grade comes before the description on purpose. 5 of them are backed by a published review, so both figures on those cards are derived from the tiers on the page they link to. The remaining card says so where a review has not been run, because a grade or a count this site has not derived is one it does not publish.
-
REPunapproved
BPC-157
Pentadecapeptide BPC, 15 amino acids
- grade
- B
- completed human studies
- 5
- status
- unapproved
The best-selling compound in the category, and the letter points the other way from what a reader expects. It has been randomized against placebo, in ulcerative colitis in 2005, and the between-group difference crossed zero. That study was never published beyond a conference abstract, everything else published in people is uncontrolled, and the route almost every buyer uses has never been studied in anything.
-
REPunapproved
TB-500
Thymosin beta-4 fragment, 7 amino acids
- grade
- D
- completed human studies
- 0
- status
- unapproved
One registry record names TB-500, and it states in its own registered text that it is a fictional example of a registry-style record. Of the eighteen registrations usually counted for the compound, seventeen tested thymosin beta-4, the full protein this peptide is a fragment of, in dry eye and corneal wound healing. A fragment does not inherit the parent protein's grade.
-
METapproved drug
Semaglutide
GLP-1 receptor agonist, 31 amino acids
- grade
- not reviewed yet
- completed human studies
- not reviewed yet
- status
- approved
The best-evidenced compound on this list, and the only one that reached approval. Both facts belong on the same page. This site publishes no grade for it yet, because the source review behind a grade has not been run.
-
REPunapproved
GHK-Cu
Copper tripeptide-1, 3 amino acids
- grade
- B
- completed human studies
- 2
- status
- no approval
The letter records how much research exists, and here it points the other way from what a reader expects: both randomized trials came back with no difference from their control on every measure an assessor made. That direction cannot fit in a letter, so it is written out here and again beside the badge on the page.
-
GHSunapproved
CJC-1295 with DAC
Growth hormone releasing hormone analog, 29 amino acids
- grade
- C
- completed human studies
- 3
- status
- unapproved
Better pharmacology than almost anything in this catalog and no outcome evidence at all. Randomized trials measured what one injection does to two hormones in blood, and the compound did what it was designed to do. Nothing has ever measured what follows from that, and the one trial that would have was terminated in 2006 without a stated reason.
-
LNGunapproved
Dihexa
Angiotensin IV analog, a modified dipeptide
- grade
- D
- completed human studies
- 0
- status
- unapproved
Sold on a mechanism whose published foundation was withdrawn. The 2014 paper connecting the behavioural results to the system this compound is sold for was retracted in April 2025, after carrying an expression of concern since 2021, and a second paper from the same programme is still flagged. A drug aimed at the same target was then tested in 554 people and missed its primary endpoint.
An index points at a claim, it does not make one. Where a card shows a grade its page has published, and every figure on that card is restated there with its source, and with an evidence tier wherever the figure is a claim about what the compound does rather than a regulatory or operational fact. The remaining cards carry no grade and no study count, and the regulatory word on each is restated with its document on the entry the card links to.
evidence
How the grades work
One scale, applied the same way to every compound, published so anyone can check it. A grade describes the quality of the research, not whether something works and not whether anyone should use it. The full derivation is on the methodology page.
-
GRADE A
Completed phase 3
large, published, replicated
Multiple completed trials in people, published, with results that hold up across more than one program. Very few compounds in this category reach it.
-
GRADE B
Human data, not settled
tested in people, not settled
A completed human study tested the use it is actually sold for and read out, and it did not settle the question. An unfinished program, trials that disagree, and trials too small to conclude from all land here. The letter says the evidence exists and stops short; it does not say why it stops short.
-
GRADE C
Human data, wrong question
studied, but not for this
This compound has been studied in people, but none of that work tested the use it is sold for. A different condition, a different route, or a different formulation. The easiest grade to misread.
-
GRADE D
Animals and anecdote
no completed human trial
Rodent studies, case reports, forum accounts. Sometimes a lot of rodent studies. It is still not evidence that something works in a person.
the gap
Completed human efficacy trials for the best-selling compound
Completed, published human efficacy trials for BPC-157:
0
Zero, and that number is the most useful thing a reader can know about the best-selling compound in this category. It has been randomized against placebo twice, both times in the early 2000s by the company developing it, and neither study was ever published beyond a conference abstract. The one that measured effectiveness, in 53 people with ulcerative colitis, reported a difference against placebo whose confidence interval crossed zero. Three more human studies are published, all uncontrolled, covering 31 patients between them by routes almost nobody uses, and in July 2026 FDA told its own advisory committee the record was not enough to reach a conclusion on effectiveness. Past that it is animal studies and community reports, and that is the weight the claims made for this compound are resting on.
- registry records
- 3
- completed and published
- 0
- evidence grade
- B
Every count here is restated on the BPC-157 evidence review, where each study and each registry record appears with its identifier, its design, its result and the date it was last checked, and where one of the three records is read alongside the sponsor account it sits in. FDA set out its own reading of the BPC-157 record to an advisory committee in July 2026, and we have summarised what that meeting did and did not do in the 503A record.
guides
Recent guides
Every guide is dated, every claim carries a citation, and every page says who checked it. Corrections stay visible at the bottom of the page instead of being edited away. The rows below are the most recently published guides, ordered by their own publication dates, and the grade and source count on each are read from the page it links to.
-
GUIDE 1
[COS · grade B]Acetyl hexapeptide-8: benefits, side effects and the evidence
The peptide behind the botox-in-a-cream category, read from primary records: what a US Food and Drug Administration laboratory measured in every layer of human skin, what two National Institutes of Health trials posted, and what the cosmetics industry's own safety panel concluded in 2025. 24 numbered sources.
-
GUIDE 2
[GHS · grade D]CJC-1295 without DAC: benefits, side effects and the evidence
The version of CJC-1295 most people buy, and the one nobody has studied. Every duration, potency and pulse-pattern figure quoted for it was measured on a different product. 14 numbered sources.
-
GUIDE 3
[GHS · grade C]CJC-1295 with DAC: benefits, side effects and the evidence
A compound that raises growth hormone for a week from one injection, whose entire human record measures the hormone and never measured a person, and whose only registered trial stopped in 2006 without saying why. 16 numbered sources.
-
GUIDE 4
[COG · grade D]Dihexa: benefits, side effects and the evidence
An angiotensin IV analog covered claim by claim: the mouse and rat results that stand, the 2014 mechanism paper that was retracted in 2025, and the 554 participant trial of a drug aimed at the same target. 12 numbered sources.
questions
The questions people ask first
Before anyone picks a compound they usually want to know what these things are, where they stand in law, and what the evidence behind them looks like. Each page below answers one of those against the primary documents.
- Are peptides steroids? Two different classes of molecule, built differently and governed by different parts of federal law. Here is what each one is, and which document draws the line.
- Are peptides legal in the US? The answer has layers, and the layer a compound sits in decides everything. Here is each one, with the statute, regulation or agency document behind it.
- Do peptides work? The evidence sits per compound and per claim, which is why every claim on this site carries a tier. Three worked examples show what that looks like in practice.